COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

开始日期2026-06-15

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+5]

NCT07457918

/ Recruiting临床3期

COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:
* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).
* To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.
Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0/+ 8 days).
If participants still have warts present after 4 additional treatments of YCANTH (VP-102/TO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:
vesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102/TO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.
Treatment:
For participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).
In addition, eligibility for participation in the LTFU study must have been determined, and informed consent/assent for participation in this LTFU study obtained. YCANTH (VP-102/TO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102/TO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.

开始日期2026-03-11

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+5]

NCT07246590

/ Recruiting临床3期

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

开始日期2025-12-17

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+4]

100 项与斑蝥素相关的临床结果

登录后查看更多信息

100 项与斑蝥素相关的转化医学

登录后查看更多信息

100 项与斑蝥素相关的专利（医药）

登录后查看更多信息

1,140

项与斑蝥素相关的文献（医药）

2026-08-01·Materials Today Bio

Cantharidin-manganese based cocktail nanoplatform Co-activating ferroptosis and STING for enhanced HCC immunotherapy

Article

作者: Ma, Mengtian ; Xia, Xinhua ; Wang, Shengmei ; Zhong, Dong ; Li, Jianyu ; Tao, Xueqing ; Deng, Guiming ; Guo, Qiuyan ; Zhang, Kun

Hepatocellular carcinoma (HCC) is often identified during its advanced phases, where therapeutic choices are constrained and patient prognosis is generally poor, creating a critical need for innovative treatment approaches. Despite the promise of immunotherapy, its efficacy is frequently constrained by the immunosuppressive tumor microenvironment (TME). To address this, we developed a multifunctional nanoplatform (CTD/MM@BSA) via a facile "one-pot" method, co-delivering the chemotherapeutic agent cantharidin (CTD) and manganese ions (Mn²⁺) using bovine serum albumin (BSA). This platform leverages the synergistic interplay between ferroptosis induction and cGAS-STING pathway activation to remodel the TME. Upon internalization and subsequent release within tumor cells, CTD and Mn²⁺ act synergistically to boost intracellular ROS levels. This elevation promotes the induction of ferroptosis and ICD. The process culminates in the emission of DAMPs, which in turn activate the maturation of dendritic cells. Simultaneously, DNA damage triggered by CTD acts synergistically with the heightened sensitivity of cGAS to DNA in the presence of Mn²⁺, leading to a marked amplification of cGAS-STING pathway activation and the subsequent production of type I interferons. This bidirectional ferroptosis-immunity activation cascade effectively reverses immunosuppression, promoting cytotoxic T-cell responses. It markedly suppresses tumor growth and metastasis while extending the survival of mice. Moreover, when combined with an anti-PD-L1 antibody (aPD-L1), the therapy demonstrates a stronger synergistic anti-tumor effect. This study overcomes the limitations of free CTD (hepatorenal toxicity) and Mn²⁺ (poor tumor accumulation), offering a potent and targeted strategy to remodel the TME and boost anti-tumor immunity for HCC therapy.

2026-07-01·ARCHIVES OF TOXICOLOGY

CYP2C19 as a key enzyme in the metabolism of cantharidin in Huh-7 cells and mice

Article

作者: Liu, Yijia ; Zhang, Jie ; Ma, Jinghong ; Liu, Liang ; Wang, Qing K ; Song, Kaiyin ; Yao, Yufeng ; Zhou, Xiaowei ; Lyu, Feng ; Tian, Tongtong ; Wu, Yifan

Cantharidin (CTD), a traditional Chinese medicinal with a long history of use, exhibits broad-spectrum antitumor properties. However, its clinical application is severely limited by its inherent toxicity. Cytochrome P450 (CYP) enzymes are major phase I drug-metabolizing enzymes in clinical settings. To date, however, no enzymes responsible for the metabolism of CTD have been reported yet. In this study, specific CYP450 isoforms involved in CTD metabolism were identified and validated. We first performed in vitro experiments using Huh-7 cells to screen for enzymes capable of metabolizing CTD. Subsequent in vivo studies were conducted by tail vein injection of adeno-associated virus (AAV8-CYP2C19) to achieve CYP2C19 overexpression in mice. Mice were then administered CTD (1.5 mg/kg) by gavage, and survival was monitored. Cardiac injury was evaluated using Hematoxylin-Eosin (HE) staining and Masson staining, while cardiac function was assessed by echocardiography. Myocardial apoptosis was examined by TUNEL staining and Western blotting. The expression levels of genes encoding related enzymes were measured by Real-Time quantitative PCR. GC-MS was employed to quantify CTD concentrations in cell culture medium, mouse blood, and mouse liver tissues. Additionally, single-nucleotide polymorphism (SNP) analysis was performed on human samples. Our in vitro results identified CYP2C19 as a key enzyme involved in CTD metabolism. Consistent with this, AAV8-CYP2C19‑mediated overexpression in mice significantly accelerated CTD metabolism. CTD administration induced cardiac dysfunction, particularly within 6 h of gavage, as evidenced by a rapid decline in cardiac output. Histological analysis revealed myocardial damage characterized by inflammatory cell infiltration and collagen fiber deposition. TUNEL staining and Western blotting further confirmed increased cardiomyocyte apoptosis following CTD exposure. GC-MS analysis demonstrated reduced CTD concentrations in the blood and liver of AAV8‑CYP2C19‑treated mice, which corresponded to alleviated myocardial injury in the AAV8-CYP2C19 + CTD group. In human samples, liver samples from patients who died of CTD-induced toxicity were found to carry the CYP2C19*2 SNP, a variant associated with the slow-metabolizer phenotype. Collectively, our findings demonstrate, for the first time, that CTD is metabolized by CYP2C19. These results suggest that genetic testing for CYP2C19 polymorphisms could be performed prior to CTD-based cancer therapy, thereby facilitating precision medicine approaches that minimize toxicity and improve therapeutic efficacy.

2026-07-01·HISTOLOGY AND HISTOPATHOLOGY

Cantharidic acid causes mitochondrial dysfunction via the Nrf2/HO-1/GPX4 pathway to inhibit colorectal cancer progression.

Article

作者: Li, Yin ; Zhang, Dongyun ; Dai, Shulin ; Wei, Yan ; Huang, Wei ; Zhang, Ting ; Niu, Mingliao ; Wang, Xiaoyu

BACKGROUND:

Cantharidic acid (CA) is a cantharidin analog and has antitumor effects. This study aimed to investigate the antitumor activity of CA against colorectal cancer (CRC) and the underlying mechanisms of this activity.

METHODS:

The impact of CA on the viability of the normal FHC cell line was evaluated by the CCK-8 assay. The malignant behavior of CRC cells was determined using the CCK-8 assay, colony formation assay, Transwell assay, and an LDH commercial kit. The surviving and apoptotic cell numbers were examined via flow cytometry and calcein-AM/PI staining. The ultrastructure of the mitochondria was observed, and the concentration of mtDNA was detected via RT-qPCR. A subcutaneous xenograft tumor model in nude mice was established, and pathological staining was used to assess apoptosis and changes in protein expression. Western blotting was used to evaluate the levels of nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1)/glutathione peroxidase 4 (GPX4) pathway-related proteins and mitochondrial damage-related proteins.

RESULTS:

CA did not significantly affect FHC viability but was able to reduce CRC cell viability, decrease colony-forming ability, inhibit migration and invasion, and induce apoptosis. CA treatment disrupted mitochondrial morphology and structure and caused a decrease in mitochondrial membrane potential, ATP production, and mtDNA concentration. Treatment with Mito-TEMPO (a mitochondrion-targeted antioxidant) reversed the effects of CA treatment on the above metrics. Furthermore, CA blocked the Nrf2/HO-1/GPX4 pathway, whereas the Nrf2 agonist TBHQ alleviated CA-induced mitochondrial dysfunction. CA treatment decreased the volume and mass of tumor tissue, inhibited cell proliferation, and promoted apoptosis. Notably, CA also led to mitochondrial dysfunction in vivo, which was effectively mitigated by TBHQ.

CONCLUSION:

CA blocks the Nrf2/HO-1/GPX4 pathway, causing mitochondrial dysfunction and apoptosis, and thus inhibits the malignant progression of CRC. CA has potential as a therapeutic agent for CRC.

155

项与斑蝥素相关的新闻（医药）

2026-08-27

·BioSpace

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced completion of enrollment of the first pivotal clinical trial (COVE-2) of its global Phase 3 program evaluating YCANTH ® (VP-102) for the treatment of common warts. “I am very pleased to announce substantial progress in our global Phase 3 program seeking to expand the label for YCANTH to include common warts,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “We have now completed enrollment in the first pivotal trial, COVE-2, after conducting a per-protocol interim analysis evaluating powering assumptions. The interim analysis confirms that no additional subjects are recommended. We have also achieved greater than 50% of the current targeted enrollment in the second pivotal trial, COVE-3, ahead of schedule. I would like to recognize the significant effort by all involved and especially our development partner for the program, Torii Pharmaceutical,” Dr. Rieger continued. “We anticipate topline data from COVE-2 in the first quarter of 2027 and currently expect the remaining topline data for the program will be available by mid-2027. The potential label expansion into common warts is a cornerstone of our long-term commercial strategy and could allow us to leverage our existing sales and marketing team, call points and relationships with KOLs and payors to provide a high degree of synergy with the promotion of YCANTH for the treatment of molluscum. This clinical progress is a major step towards achieving that strategy,” said Dr. Rieger. Noah L. Rosenberg M.D., Chief Medical Officer of Verrica, added, “Patients often try minimally effective over-the-counter therapies, with limited success and frequent recurrence of warts. If the Phase 3 program is successful, YCANTH has the potential to become the first FDA-approved prescription drug treatment for common warts, one of the largest unmet needs in dermatology. I would like to thank our clinical team, the patients, clinical sites and our external partners, including Torii, for their work to advance the program to this milestone.” Global Phase 3 Program Verrica has previously completed a Phase 2 study (COVE-1) which demonstrated clinically meaningful results, including a reduction in number of common warts, patients with complete clearance of common warts and durability of clearance in many patients. The global Phase 3 program has been designed to include two double-blind, randomized, vehicle-controlled studies (COVE-2 and COVE-3) evaluating the efficacy and safety of VP-102/TO-208 when applied once every 21 days for a total of up to four applications in patients aged 2+ years with common warts. The interim analysis was done by an independent statistician, and the study remains fully blinded to the company and study team. The COVE-2 study enrolled patients in the U.S. only and the COVE-3 study is enrolling patients in the U.S. and Japan. Based on the results of the Phase 3 program, Verrica and its Japanese development partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., intend to seek marketing approval in the U.S. and Japan, respectively. The program also includes a supportive long-term follow-up study (COVE-4) and a pharmacokinetics study (COVE-5). Verrica and Torii will split the costs of the global Phase 3 program with Verrica on a 50/50 basis, and Torii will fund the first $40 million of trial costs, representing approximately 90% of the current trial budget. Verrica’s portion of the costs is expected to be paid out of future transfer price payments, milestones and royalties arising from sales of YCANTH in Japan. Market Opportunity in Common Warts With a prevalence of approximately 22 million patients in the U.S. alone and no FDA-approved prescription drug therapies, common warts represent one of the largest unmet needs in all of dermatology, which Verrica believes could represent a multibillion-dollar commercial opportunity. In the United States, approximately 50% of the patients who seek treatment for common warts are children. About YCANTH ® (VP-102) YCANTH ® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information. YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the US and Japan for use in the treatment of common warts. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102), the timing of clinical data availability, including the timing of topline results from COVE-2, the recruitment and enrollment of patients in clinical trials, including the timing of complete enrollment in COVE-3, and the potential approval of YCANTH in common warts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

2026-08-07

·BioSpace

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 — — Facility provided by an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder — WEST CHESTER, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the closing of a credit facility of up to $27.5 million with an entity controlled by Paul B. Manning, Verrica’s largest shareholder. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “This facility provides Verrica with a meaningful source of non-dilutive capital and supports the continued growth of our YCANTH® business as well as the global Phase 3 program studying YCANTH for the treatment of common warts,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Importantly, this facility provides potential for no scheduled payments of interest or principal until maturity and did not include the issuance of any warrants. This flexibility will allow Verrica to maximize deployment of its cash resources toward advancing its business and pipeline. I would like to thank Paul Manning for his continued support of Verrica and for his confidence in our team to execute on our commercial and development initiatives.” Dr. Rieger continued, “We are seeing increasing adoption of YCANTH for molluscum and we have now secured the capital needed to advance the global Phase 3 common warts program, which includes two pivotal studies with data readouts expected by mid-2027. If approved, YCANTH could become the first FDA-approved therapy for the treatment of common warts, a condition affecting approximately 22 million patients in the US alone. We believe that a label expansion for YCANTH in common warts could represent a commercial opportunity several times larger than molluscum, given the unmet need and the millions of individuals impacted by this condition each year. Based on our current operating plan, we believe the full $27.5 million that may be available under the facility could extend our cash runway into 2028.” Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of the Board of Directors of Verrica, commented, “I am proud to support Verrica’s continued growth by providing access to the additional capital it needs to achieve its goals. Verrica’s commercial performance has clearly strengthened over the last year, and I expect continued growth into the future. I have believed in the potential of YCANTH since I first invested in Verrica in 2015, and I am excited about what the future holds for Verrica, its shareholders and, most importantly, the patients it serves.” Terms of the Credit Agreement Under the terms of credit agreement, Verrica may borrow up to $12.5 million under the facility immediately, with an additional $15.0 million becoming available upon Verrica’s achievement of certain revenue, growth and other operational milestones, in each case subject to customary conditions. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind with a maturity date of December 31, 2030, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries. Additional information about the terms of the credit agreement can be found in Verrica’s Quarterly Report on Form 10-Q to be filed on August 6, 2026. About YCANTH® (VP-102) YCANTH ® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH in the US was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information. YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is also now being studied in a global phase 3 program in the US and Japan for use in the treatment of common warts. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrrica’s ability to borrow funds under the credit facility, Verrica’s achievement of milestones set forth in the credit agreement, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

临床3期上市批准引进/卖出临床结果

2026-07-30

·BioSpace

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, , or by clicking here . A replay of the webcast will be archived on Verrica’s website for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

100 项与斑蝥素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11745	斑蝥素	D11AF	DB12328

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
传染性软疣	美国	Verrica Pharmaceuticals, Inc.	2023-07-21
尖锐湿疣	中国	海南回元堂药业有限公司	2015-07-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
跖疣	临床3期	美国	Verrica Pharmaceuticals, Inc.	2025-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAD2025	临床3期	传染性软疣	303	TO-208	鹽襯簾鏇糧醖淵夢淵鬱(積壓餘願壓觸網齋鏇鬱) = 窪膚繭網鹹蓋繭製鏇糧蓋夢蓋憲築範壓積夢淵 (鹽觸構簾獵鹽鬱餘繭廠 ) 更多	积极	2025-03-07
				Placebo	鹽襯簾鏇糧醖淵夢淵鬱(積壓餘願壓觸網齋鏇鬱) = 製艱製選範範獵構憲衊蓋夢蓋憲築範壓積夢淵 (鹽觸構簾獵鹽鬱餘繭廠 ) 更多
GlobeNewswire 人工标引	临床3期	传染性软疣	-	TO-208	網醖築壓繭遞窪蓋鏇鑰(淵鏇製觸艱積顧衊糧遞) = statistically significant versus placebo 壓簾鏇淵襯鑰襯鬱鏇餘 (鑰齋觸觸網廠簾構簾選 )	积极	2023-12-15
				Placebo
NCT03377803 \| NCT03377790 (FDA) 人工标引	临床3期	传染性软疣	528	YCANTH (Trial 1)	淵壓選餘選構積願窪鹽(鑰繭鹹簾積構簾鏇製鏇) = 醖蓋簾廠齋鑰簾遞衊糧繭選範網簾膚顧構襯鹽 (築艱襯艱衊獵顧齋範鏇 ) 更多	积极	2023-07-21
				Vehicle (Trial 1)	淵壓選餘選構積願窪鹽(鑰繭鹹簾積構簾鏇製鏇) = 範願製餘願簾築鹹製願繭選範網簾膚顧構襯鹽 (築艱襯艱衊獵顧齋範鏇 ) 更多
NCT03377803 (CAMP-2, CTgov)	临床3期	传染性软疣	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	築製膚蓋齋窪積構夢餘 = 鏇膚遞蓋襯繭鏇廠構窪簾選繭繭餘製積顧繭醖 (鑰壓壓壓遞願製製鬱窪, 簾夢憲鹽積築選構顧夢 ~ 鹽積選範顧鬱顧廠衊觸) 更多	-	2021-12-14
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	築製膚蓋齋窪積構夢餘 = 襯範蓋鹹獵鏇範觸鏇膚簾選繭繭餘製積顧繭醖 (鑰壓壓壓遞願製製鬱窪, 淵鑰築窪遞壓獵壓築壓 ~ 窪獵鑰製餘蓋齋鏇憲壓) 更多
NCT03377790 (CAMP-1, CTgov)	临床3期	传染性软疣	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	製範獵觸憲衊積夢壓淵 = 遞齋選願餘窪製觸襯網膚糧鹽膚鏇廠醖構遞鬱 (夢鑰獵網鏇鏇齋餘獵壓, 憲壓糧鑰淵鑰範製廠鑰 ~ 範夢繭簾鬱繭獵衊膚遞) 更多	-	2021-12-14
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	製範獵觸憲衊積夢壓淵 = 廠築構餘獵襯蓋繭壓壓膚糧鹽膚鏇廠醖構遞鬱 (夢鑰獵網鏇鏇齋餘獵壓, 糧繭糧積壓糧繭壓積蓋 ~ 餘繭構鏇選鹹繭觸襯積) 更多
NCT03981822 (Pubmed \| Am J Clin Dermatol) 人工标引	临床2期	尖锐湿疣	-	VP-102	夢餘膚築選夢構鏇鏇窪(製選遞網鏇糧膚鑰糧膚) = 壓鹹蓋糧餘襯壓簾鹽艱繭鹽廠願醖糧壓選醖蓋 (齋鏇窪淵網願積壓選糧 ) 更多	积极	2021-11-01
				Placebo	夢餘膚築選夢構鏇鏇窪(製選遞網鏇糧膚鑰糧膚) = 繭顧鹽鏇遞願範膚簾膚繭鹽廠願醖糧壓選醖蓋 (齋鏇窪淵網願積壓選糧 ) 更多
NCT03487549 (COVE-1, Pubmed) 人工标引	临床2期	疣	56	VP-102 (Cohort 1)	齋築鬱鏇蓋鬱顧積選鹽(網構遞積簾廠築蓋鬱蓋) = 鹹構顧鬱醖鑰膚衊鏇壓構膚壓廠範觸餘醖壓築 (選範繭顧夢窪醖餘鬱廠 )	积极	2021-10-01
				VP-102 (Cohort 2)	齋築鬱鏇蓋鬱顧積選鹽(網構遞積簾廠築蓋鬱蓋) = 製遞壓糧憲齋鏇築鑰窪構膚壓廠範觸餘醖壓築 (選範繭顧夢窪醖餘鬱廠 )
NCT03981822 (CARE-1, CTgov)	临床2期	尖锐湿疣	105	VP-102 (Part B Pooled With Part A: VP-102 6-hour)	夢醖願選願蓋壓糧製淵: P-Value = 0.0048 更多	-	2021-09-22
				Placebo (Part B Pooled With Part A: Placebo 6-hour)
NCT03487549 (COVE-1, CTgov)	临床2期	疣	56	VP-102 (Cohort 1)	構願膚鹽製網觸構遞願 = 醖蓋衊鬱構衊膚積鏇顧淵製鬱襯鬱膚獵衊壓顧 (壓淵膚遞鑰憲觸壓觸窪, 繭選壓鹹壓憲蓋夢繭窪 ~ 鬱築夢淵鹹簾夢窪夢艱) 更多	-	2021-09-01
				VP-102 (VP-102 - Cohort 2)	襯餘構壓衊鹽觸壓窪鹽 = 壓鹹糧齋齋簾餘範簾鏇餘膚夢範糧構遞壓鑰襯 (鏇蓋網鑰選鏇顧願獵憲, 選壓襯鏇選衊繭齋艱築 ~ 鑰鹽廠顧範構窪鑰顧襯) 更多
NCT03186378 (CTgov)	临床2期	传染性软疣	33	VP-102 with applicator (Exposure Group)	鏇積遞壓夢簾製艱醖齋 = 構網選顧鑰糧積夢選壓網艱鏇獵鹹廠鏇鬱製網 (顧餘積積窪築餘鏇構簾, 廠齋簾網鹽積壓膚鹹願 ~ 膚積簾憲遞鹽艱築鏇願) 更多	-	2021-08-09
				VP-102 with applicator (Standard Group)	鏇積遞壓夢簾製艱醖齋 = 顧顧壓鑰窪鏇壓鹽鬱醖網艱鏇獵鹹廠鏇鬱製網 (顧餘積積窪築餘鏇構簾, 醖遞網廠鏇襯範積餘膚 ~ 選構選廠遞遞網鬱憲網) 更多